EANS-Adhoc: Marinomed Biotech AG: Greenshoe option fully exercised

--------------------------------------------------------------------------------
Disclosed inside information pursuant to article 17 Market Abuse Regulation
(MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

No Keyword
28.02.2019

Vienna - Vienna, 28 February 2019. Marinomed Biotech AG announces that the
greenshoe option from the IPO of 39,000 shares at the offer price of EUR 75 per
share was fully exercised. Erste Group Bank AG, acting as stabilising manager,
has not conducted any stabilisation activities since the initial listing of the
Marinomed shares on 1 February 2019.

After exercising the greenshoe option and subject to the registration of the
capital increase in the commercial register planned for next week, the share
capital amounts to EUR 1,469,772, split into 1,469,772 voting shares, and the
free float amounts to around 39%.

About Marinomed Biotech AG
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the
development of innovative products derived from patent protected technology
platforms to treat respiratory and ophthalmic conditions. The Carragelose®
platform comprises innovative patent protected products targeting viral
infections of the respiratory tract. Carragelose® is used in nasal sprays,
throat sprays and lozenges, which are sold in more than 30 countries around the
world in collaboration with international partners. The Marinosolv® technology
platform increases the efficacy of hardly soluble compounds for the treatment of
sensitive tissues such as the eyes and nose. Further information is available at
www.marinomed.com [http://www.marinomed.com/].

Further inquiry note:
Eva Prieschl-Grassauer, PhD
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
Tel.: +43 (0)1 250 77 4460
E-mail: eva.prieschl@marinomed.com
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331
E-mail: r.mayrl@metrum.at
http://www.metrum.at

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: 0043250774460
FAX: 0043250774493
mail: office@marinomed.com
WWW: www.marinomed.com
ISIN: ATMARINOMED6, AT0000A1WD52
indexes:
stockmarkets: Wien
language: English

Original-Content von: Marinomed Biotech AG, übermittelt durch news aktuell